Sung Jun Ma1, Michael Cummings2, Lucas M Serra1, Yusef A Syed1, Gregory M Hermann1, Yuhchyau Chen2, Michael T Milano2, Anurag K Singh3, Jorge A Gomez-Suescun1, Deepinder P Singh2. 1. University at Buffalo, The State University of New York, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY; Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY. 2. Department of Radiation Oncology, Wilmot Cancer Institute at Strong Memorial Hospital, Rochester, NY. 3. University at Buffalo, The State University of New York, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY; Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: Anurag.Singh@RoswellPark.org.
Abstract
PURPOSE: To evaluate differences in outcomes of early-stage peripheral non-small-cell lung cancer (NSCLC) treated with either 3- or 5-fraction stereotactic body radiotherapy (SBRT) at 2 institutions. PATIENTS AND METHODS: Patients diagnosed with peripherally located early-stage NSCLC who received either a median dose of 60 Gy (interquartile range [IQR], 60-60, biologically effective dose, 151-151) in 3 fractions or a median dose of 50 Gy (IQR, 50-50, biologically effective dose, 94-94) in 5 fractions were included in this study. All data were retrospectively collected and reviewed in an institutional review board-approved database. RESULTS: A total of 192 lesions in 192 patients were identified: 94 received 3-fraction SBRT and 98 received 5-fraction SBRT. Patients in the 5-fraction cohort had significantly smaller tumors (P = .0021). Larger tumor size was associated with worse overall survival (hazard ratio, 1.40, P = .0013) for all patients. A single grade 3 toxicity was reported in each cohort. A propensity score-matched cohort of 94 patients was constructed with a median follow-up of 29.3 months (IQR, 17.3-44.6) for the 3-fraction cohort and 31.0 months (IQR, 17.0-48.5) for the 5-fraction cohort (P = .84). There were no statistically significant differences between these 2 cohorts in overall survival (P = .33), progression-free survival (P = .40), local failure (P = .86), and nodal or distant failure (P = .57) at 2 years. CONCLUSION: The 3- and 5-fraction SBRT regimens for early-stage peripheral NSCLC had comparable clinical outcomes. Both regimens were well tolerated. A large tumor size was an adverse prognostic factor for worse survival.
PURPOSE: To evaluate differences in outcomes of early-stage peripheral non-small-cell lung cancer (NSCLC) treated with either 3- or 5-fraction stereotactic body radiotherapy (SBRT) at 2 institutions. PATIENTS AND METHODS: Patients diagnosed with peripherally located early-stage NSCLC who received either a median dose of 60 Gy (interquartile range [IQR], 60-60, biologically effective dose, 151-151) in 3 fractions or a median dose of 50 Gy (IQR, 50-50, biologically effective dose, 94-94) in 5 fractions were included in this study. All data were retrospectively collected and reviewed in an institutional review board-approved database. RESULTS: A total of 192 lesions in 192 patients were identified: 94 received 3-fraction SBRT and 98 received 5-fraction SBRT. Patients in the 5-fraction cohort had significantly smaller tumors (P = .0021). Larger tumor size was associated with worse overall survival (hazard ratio, 1.40, P = .0013) for all patients. A single grade 3 toxicity was reported in each cohort. A propensity score-matched cohort of 94 patients was constructed with a median follow-up of 29.3 months (IQR, 17.3-44.6) for the 3-fraction cohort and 31.0 months (IQR, 17.0-48.5) for the 5-fraction cohort (P = .84). There were no statistically significant differences between these 2 cohorts in overall survival (P = .33), progression-free survival (P = .40), local failure (P = .86), and nodal or distant failure (P = .57) at 2 years. CONCLUSION: The 3- and 5-fraction SBRT regimens for early-stage peripheral NSCLC had comparable clinical outcomes. Both regimens were well tolerated. A large tumor size was an adverse prognostic factor for worse survival.
Authors: Anurag K Singh; Jorge A Gomez-Suescun; Kevin L Stephans; Jeffrey A Bogart; Gregory M Hermann; Lili Tian; Adrienne Groman; Gregory M Videtic Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-22 Impact factor: 7.038
Authors: Bindu V Manyam; Kyle Verdecchia; Kevin Rogacki; Chandana A Reddy; Tingliang Zhuang; Gregory M M Videtic; Joseph T Azok; Kevin L Stephans Journal: J Radiosurg SBRT Date: 2019
Authors: Austin J Bartl; Mary Mahoney; Mark W Hennon; Sai Yendamuri; Gregory M M Videtic; Kevin L Stephans; Shankar Siva; Mark K Farrugia; Sung Jun Ma; Anurag K Singh Journal: Cancers (Basel) Date: 2022-02-03 Impact factor: 6.639